Go to every biotech YMB, post this message. We need a lot more newbies to push price up. God dzmn it!
People sold calls to protect their shares. You just misread here.
The key is to write calls and collect premiums. The stock price will likely be flat before May 26. Use options to make money. Adn and I have collected handsome $$$ so far.
Look at the rlyp market cap, i don't think it can do down much further. MNKD is about the same market cap as rlyp now and they have a failed drug. Not to mention MNKD has much more debt. Watch the RX number grow MoM and pps will follow. Non-dilutive financing will come in Q3 when sales are better.
Good plan. About $3 premium for your share. My CCs give me some cushion, too. I can rewrite to lower strike prices tomorrow to get more premiums if pps is still going down. GL!
Does this company have a poison pill for hostile take over? Market cap is 600 M with 280 M cash. Veltassa is only worth 320 M? ZS-9 is 2.7 B!!
He probably lost more than anyone here. I doubt anyone will buy because he pumped. I sold deep in the money covered call Apr 17 and Jun 20 earlier. Hope it can cover 2/3 of loss. Maybe buy back and write again but I doubt options will be any juicy like before. It's all about monthly sales now.
I gave you a thumb down because you have missing variables in your equation. Stop for a minute and think about it.
Fact: 280 mil cash @ Q3, 2015
Assumption: 50 mil per quarter burn rate
Sales for 2016: analyst consensus 47 mil which is very conservative. Well, let's use it.
End of 2016: We have 280 - 250 (5 quarter burn) + 47= 77 mil cash
2017 revenue -- 150 mil another conservative number
End of 2017: We have 150+77-200 = 27 mil cash
2018 revenue -- 250 mil once again very conservative number
End of 2018: We have 250+27-200 = 77 mil cash
Now there are incomes from Vifor up to 120 mil milestone payment and 40 mil upfront payment and expense for 10 mil to SNY. Also about 15 mil stock option each year is non-cash item. If you want to fine tune.
I can see they open loan facility sometimes @ 2017. Amount should not be big.
Billyray, could you tell me where do they need $375 mil cash for?
That is the most likely scenario. FDA can't approve chronic use if there are no long term safety data. Interim result does not count.